Climb Bio, Inc.
CLYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.25 | 0.08 | -0.02 |
| FCF Yield | -17.95% | -9.75% | -18.14% | -37.57% |
| EV / EBITDA | 0.00 | -2.94 | -3.61 | -1.38 |
| Quality | ||||
| ROIC | -38.61% | -37.19% | -34.85% | -21.33% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.21 | 0.59 | 0.83 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 24.45% | 44.88% | -3.60% | -155.87% |
| Safety | ||||
| Net Debt / EBITDA | 2.86 | 2.30 | 0.96 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |